Acurx Pharmaceuticals, Inc. ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today ...
Callio Therapeutics is developing novel dual-payload antibody-drug conjugates (ADCs) designed to address resistance to existing cancer therapies, ...
Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion ...
This study characterizes several novel activities of SARS-CoV-2 helicase nsp13, providing valuable insights into potentially new functions of this essential RNA-processing enzyme in the virus life ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...
In this valuable study, the authors develop new approaches to investigate mRNA imprinting, a phenomenon in which RNA-protein complexes form in the nucleus to influence the fate of transcripts in the ...
Model Medicines receives US patent related to MDL-001 in its broad antiviral Intellectual Property portfolio: San Diego, California Saturday, April 18, 2026, 12:00 Hrs [IST] Model ...
Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royaltiesAmoytop to fund its development program in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results